Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Aurametrix | OTHER |
Not provided
Not provided
Not provided
During the study, members of different online and offline communities will be followed post COVID-19 vaccination.
Injection-site (local) and systemic reaction data will be assessed on vaccination day and afterwards using either web surveys or personal communication, depending on study participant preference.
Hypothesis to be tested: The safety profile and the magnitude and durability of immune responses to the COVID-19 vaccines as well as adverse reactions depend on health conditions, metabolism and microbiomes.
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was declared a Public Health Emergency of International Concern in January 2020 and upgraded to pandemic in March 2020. First vaccines to prevent COVID-19 were authorized for emergency use in the US in December 2020, but a number of unknowns still remains. One of these unknowns is the relationship of the microbiota, gut dysbiosis and impaired metabolism with active immunity to pathogens and vaccines and tolerance to antigens. Study groups will be based on age, metabolism, donated diagnostic test results and self-reported symptoms. Data will be collected continuously via surveys and investigator-participant interactions, as needed. Statistical methods used will be the ones with the greatest power.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 80 years of age or older | Individuals 80-89, 90-99, 100 years of age and older who received COVID-19 vaccine |
| |
| 60-79 years of age | Individuals 60-69 and 70-79 years of age who received COVID-19 vaccine |
| |
| 40-59 years of age | Individuals in 40-49, 50-59 age range who received COVID-19 vaccine |
| |
| 18-39 years of age | Individuals in 18-29, 30-39 age range who received COVID-19 vaccine |
| |
| MEBO/PATM | Individuals with present or past MEBO/PATM symptoms who received COVID-19 vaccine |
| |
| Chronic Disease | Individuals with self-reported chronic health conditions who received COVID-19 vaccine |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| COVID-19 vaccines | Biological | Emergency-use authorized COVID-19 vaccines |
|
| Measure | Description | Time Frame |
|---|---|---|
| Adverse reactions/events | Percentage of occurrence, types, duration and severity of adverse events occurring within 10 days post-doses 1 and 2 | 10 days after any dose of study intervention. |
| Measure | Description | Time Frame |
|---|---|---|
| Long-term adverse events | Percentage of occurrence, types, duration and severity of adverse events throughout study period | Throughout the study period, until 12 months post-final-dose |
| Incidence of COVID-19 cases |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Individuals 18 or older interested in vaccinating
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Irene Gabashvili, PhD | Mebo Research, Inc. | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| MEBO Research, Inc | Miami | Florida | 33175 | United States | ||
| Kahite |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36309347 | Result | Gabashvili IS. The Incidence and Effect of Adverse Events Due to COVID-19 Vaccines on Breakthrough Infections: Decentralized Observational Study With Underrepresented Groups. JMIR Form Res. 2022 Nov 4;6(11):e41914. doi: 10.2196/41914. |
| Label | URL |
|---|---|
| Study updates | View source |
Not provided
individual participant data will remain confidential, unless specifically requested to be shared by the participant
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D064420 | Drug-Related Side Effects and Adverse Reactions |
| D000069451 | Long Term Adverse Effects |
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D064419 | Chemically-Induced Disorders |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D011024 | Pneumonia, Viral |
Not provided
Not provided
| ID | Term |
|---|---|
| D000086663 | COVID-19 Vaccines |
| D000090982 | BNT162 Vaccine |
| D000090983 | 2019-nCoV Vaccine mRNA-1273 |
| D000090984 | Ad26COVS1 |
| D000090985 | ChAdOx1 nCoV-19 |
| C000722216 | sinovac COVID-19 vaccine |
| C000722768 | BIBP COVID-19 vaccine |
| C000722386 | BBV152 COVID-19 vaccine |
| C000711928 | NVX-CoV2373 adjuvated lipid nanoparticle |
| ID | Term |
|---|---|
| D014765 | Viral Vaccines |
| D014612 | Vaccines |
| D001688 | Biological Products |
| D045424 | Complex Mixtures |
Not provided
Not provided
Not provided
Not provided
Not provided
|
The number of COVID-19 cases occurring <=14 or ≥ 15 days after any dose of study intervention.
| From 14 days after completion of the 2-dose regimen up to 12 months post-final-dose |
| Vonore |
| Tennessee |
| 37885 |
| United States |
| Gabashvili | Tbilisi | Georgia |
| MEBO Research Africa | Kilifi | 8 010 | Kenya |
| Mebo Research (Uk) | London | England | W10 5LE | United Kingdom |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D014777 | Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D000087503 |
| mRNA Vaccines |
| D000087504 | Nucleic Acid-Based Vaccines |
| D014614 | Vaccines, Synthetic |
| D011994 | Recombinant Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D000941 | Antigens |
| D001685 | Biological Factors |
| D019444 | Vaccines, DNA |